A Complementary Leadership Team
OMEICOS’ is led by a dedicated team of highly skilled and experienced industry and research executives with all expertises for clinical, scientific, operational and business aspects.
Robert Fischer
CEO/CSO
Co-Founder
Robert’s passion is to transform excellent science into novel treatments for diseases with high unmet medical need. Prior to taking the lead at OMEICOS, he worked as a clinical cardiologist at the Charité – Universitätsmedizin Berlin and led and participated in many clinical and preclinical research in activities together with the Max-Delbrück-Center for Molecular Medicine. Robert holds a PhD in cardiovascular physiology from the Freie Universität zu Berlin and received Board-certification for Internal Medicine.
Robert Fischer
CEO/CSO
Co-Founder
Robert’s passion is to transform excellent science into novel treatments for diseases with high unmet medical need. Prior to taking the lead at OMEICOS, he worked as a clinical cardiologist at the Charité – Universitätsmedizin Berlin and led and participated in many clinical and preclinical research in activities together with the Max-Delbrück-Center for Molecular Medicine. Robert holds a PhD in cardiovascular physiology from the Freie Universität zu Berlin and received Board-certification for Internal Medicine.
Simon Russell
CBO, Consultancy
Simon’s career began in R&D before gaining over 20 years’ experience in senior commercial and business roles in AstraZeneca, Novartis AG and biotech. Following his last role as Head of Strategic Marketing for Biologics at Novartis, he became CBO of Creabilis Ltd leading commercial, corporate and business development ultimately negotiating its sale to Sienna Biopharmaceuticals with its subsequent IPO on NASDAQ. He is a co-founder of a biotech emerging from the Basel incubator initiative. Dr Russell studied Chemistry at the University of Oxford and received a PhD from Southampton University.
Simon Russell
CBO, Consultancy
Simon’s career began in R&D before gaining over 20 years’ experience in senior commercial and business roles in AstraZeneca, Novartis AG and biotech. Following his last role as Head of Strategic Marketing for Biologics at Novartis, he became CBO of Creabilis Ltd leading commercial, corporate and business development ultimately negotiating its sale to Sienna Biopharmaceuticals with its subsequent IPO on NASDAQ. He is a co-founder of a biotech emerging from the Basel incubator initiative. Dr Russell studied Chemistry at the University of Oxford and received a PhD from Southampton University.
Karen Uhlmann
Vice President Operations & IP
Co-Founder
Karen has more than 20 years’ experience in IP Asset Management, building and running organizations and being instrumental in raising funds, executing all different routes of commercialization. She holds a Master and a PhD in Biology from Freie Universität zu Berlin and Humboldt-Universität zu Berlin, and has earned a business degree from the Chamber of Commerce Berlin..
Karen Uhlmann
Vice President Operations & IP
Co-Founder
Karen has more than 20 years’ experience in IP Asset Management, building and running organizations and being instrumental in raising funds, executing all different routes of commercialization. She holds a Master and a PhD in Biology from Freie Universität zu Berlin and Humboldt-Universität zu Berlin, and has earned a business degree from the Chamber of Commerce Berlin..
Luciana Summo
Director
Clinical Operations
Luciana Summo has gained more than 17 years’ experience in the management of early to late-stage clinical studies in cardiovascular, hematology, antiviral, and ophthalmic indications. Prior to joining OMEICOS, she has worked at Berlin-Chemie, a subsidiary of the Menarini Group, and at NOXXON Pharma AG. Following her degree in Pharmaceutical Chemistry and Technology at the University of Bari, Dr. Summo obtained her PhD in Medicinal Chemistry in collaboration with the Institute of Pharmaceutical Science of the King’s College in London.
Luciana Summo
Director
Clinical Operations
Luciana Summo has gained more than 17 years’ experience in the management of early to late-stage clinical studies in cardiovascular, hematology, antiviral, and ophthalmic indications. Prior to joining OMEICOS, she has worked at Berlin-Chemie, a subsidiary of the Menarini Group, and at NOXXON Pharma AG. Following her degree in Pharmaceutical Chemistry and Technology at the University of Bari, Dr. Summo obtained her PhD in Medicinal Chemistry in collaboration with the Institute of Pharmaceutical Science of the King’s College in London.
Edita Bade
Head of Finance
& Controlling
Edita has gained more than 20 years of experience in various Finance, Controlling & Project Leader roles across a broad range of industries. Prior to joining OMEICOS, she supported the leadership team of an international Real Estate development company with the valuation and long-term value development projections of real estate opportunities, due diligence and acquisition/sales of these assets.
Edita Bade
Head of Finance
& Controlling
Edita has gained more than 20 years of experience in various Finance, Controlling & Project Leader roles across a broad range of industries. Prior to joining OMEICOS, she supported the leadership team of an international Real Estate development company with the valuation and long-term value development projections of real estate opportunities, due diligence and acquisition/sales of these assets.
Henk Streefkerk
Clinical Development, Consultancy
Henk, MD PhD, joined OMEICOS as Consultant ‘Clinical Development’ in September 2020. Henk is a medical doctor with a PhD in neurosurgery from University of Utrecht. He held multiple medical roles in large companies (Organon, Novartis) and biotech (Actelion, PIQUR), in translational medicine, safety, and clinical development in cardiovascular, oncology, and orphan diseases. Most recently, he was CMO of an Oncology Biotech in Basel. Henk supports OMEICOS in the overall clinical development of OMT-28.
Henk Streefkerk
Clinical Development, Consultancy
Henk, MD PhD, joined OMEICOS as Consultant ‘Clinical Development’ in September 2020. Henk is a medical doctor with a PhD in neurosurgery from University of Utrecht. He held multiple medical roles in large companies (Organon, Novartis) and biotech (Actelion, PIQUR), in translational medicine, safety, and clinical development in cardiovascular, oncology, and orphan diseases. Most recently, he was CMO of an Oncology Biotech in Basel. Henk supports OMEICOS in the overall clinical development of OMT-28.
Markus Henrich
Medicinal Chemistry and CMC, Consultancy
Markus has more than 20 years of experience in various roles in the pharmaceutical industry, amongst them Executive Director Drug Discovery and Development at Merz Pharmaceuticals GmbH. In his current role as management consultant he constantly supports OMEICOS in the field of drug discovery and development. Areas of special expertise are innovation productivity and CMC.
Markus Henrich
Medicinal Chemistry and CMC, Consultancy
Markus has more than 20 years of experience in various roles in the pharmaceutical industry, amongst them Executive Director Drug Discovery and Development at Merz Pharmaceuticals GmbH. In his current role as management consultant he constantly supports OMEICOS in the field of drug discovery and development. Areas of special expertise are innovation productivity and CMC.
An Experienced Board Supporting OMEICOS
OMEICOS’ Supervisory Board consists of professionally qualified members with many years of experience in the biotechnology and pharmaceutical industries as well as academic research in the relevant sectors for the company.
Supervisory Board
Bernhard Kirschbaum
Chairman
Bernhard Kirschbaum studied biochemistry and physiological chemistry at the University of Konstanz and received his PhD in 1989. He moved on to work at the Rockefeller University and the Pasteur Institute before making a career in the pharmaceutical industry where he covered a broad range of technological and disease areas. In his most recent position, Dr. Kirschbaum served as head of Global Research and Early Development at Merck Serono where he was a member of the board.
Bernhard Kirschbaum
Chairman
Bernhard Kirschbaum studied biochemistry and physiological chemistry at the University of Konstanz and received his PhD in 1989. He moved on to work at the Rockefeller University and the Pasteur Institute before making a career in the pharmaceutical industry where he covered a broad range of technological and disease areas. In his most recent position, Dr. Kirschbaum served as head of Global Research and Early Development at Merck Serono where he was a member of the board.
Christian Schneider
Christian Schneider, Managing Partner of Vesalius Biocapital, has been a venture capital executive for 20 years. He gained extensive experience in the areas of diagnostics, medtech, and therapeutics in the corporate life science and venture capital industry. Previously he held positions of increasing responsibility at Boehringer Mannheim, Centocor, and Johnson&Johnson. As a managing partner of VC firm PolyTechnos, he was responsible for OncoMethylome (IPO, 2006), Devgen (IPO, 2005) and Jerini (IPO, 2005). He was support partner for Addex (IPO, 2007) and BiPar (USD 500m sale to Sanofi-Aventis, 2009). He joined Vesalius in 2008 and is responsible for the portfolio companies Skyline (write-off), Activaero (EUR 130m sale to Vectura, 2014), Ventaleon, OMEICOS, Humedics and Mecuris where he serves on the boards. Dr. Schneider holds a doctorate degree in veterinary medicine (1992) and a PhD in immunology (1995), both from the University of Munich, Germany, and an MBA with focus on healthcare administration from Penn State University, Pennsylvania (1999).
Christian Schneider
Christian Schneider, Managing Partner of Vesalius Biocapital, has been a venture capital executive for 20 years. He gained extensive experience in the areas of diagnostics, medtech, and therapeutics in the corporate life science and venture capital industry. Previously he held positions of increasing responsibility at Boehringer Mannheim, Centocor, and Johnson&Johnson. As a managing partner of VC firm PolyTechnos, he was responsible for OncoMethylome (IPO, 2006), Devgen (IPO, 2005) and Jerini (IPO, 2005). He was support partner for Addex (IPO, 2007) and BiPar (USD 500m sale to Sanofi-Aventis, 2009). He joined Vesalius in 2008 and is responsible for the portfolio companies Skyline (write-off), Activaero (EUR 130m sale to Vectura, 2014), Ventaleon, OMEICOS, Humedics and Mecuris where he serves on the boards. Dr. Schneider holds a doctorate degree in veterinary medicine (1992) and a PhD in immunology (1995), both from the University of Munich, Germany, and an MBA with focus on healthcare administration from Penn State University, Pennsylvania (1999).
Peter Seiler
Head of Treasury Vice President SMS GmbH
Peter Seiler
Head of Treasury Vice President SMS GmbH
Taro Inaba
Taro Inaba is Founder and Managing Partner at Remiges Ventures. He has over 29 years of business experience including 19 years in start-up financing and company creation. At Remiges, Taro is engaged in technology sourcing, company creation, leading negotiation for investments and serving as director for seven of the Remiges’ portfolio companies. Prior to establishing Remiges Ventures, he spent 13 years at divisions of Mitsui & Co., Ltd. engaged in venture investment activities where he built and managed the biopharma investment team and investment portfolio. He served as President & CEO of Mitsui & Co. Venture Partners in Menlo Park, California from 2008 to 2009. Taro holds a B.E. in Polymer Chemistry, Kyoto University and MBA from European University. Taro is a CFA charter holder.
Taro Inaba
Taro Inaba is Founder and Managing Partner at Remiges Ventures. He has over 29 years of business experience including 19 years in start-up financing and company creation. At Remiges, Taro is engaged in technology sourcing, company creation, leading negotiation for investments and serving as director for seven of the Remiges’ portfolio companies. Prior to establishing Remiges Ventures, he spent 13 years at divisions of Mitsui & Co., Ltd. engaged in venture investment activities where he built and managed the biopharma investment team and investment portfolio. He served as President & CEO of Mitsui & Co. Venture Partners in Menlo Park, California from 2008 to 2009. Taro holds a B.E. in Polymer Chemistry, Kyoto University and MBA from European University. Taro is a CFA charter holder.
Wolf-Hagen Schunck
Wolf-Hagen Schunck is biochemist at the Max Delbrück Center for Molecular Medicine in Berlin-Buch. He has over 30 years of research experience in the field of cytochrome P450 (CYP)-derived bioactive lipid mediators. Dr. Schunck’s laboratory identified 17,18-epoxyeicosatetraenoic acid (17,18-EEQ) laying the scientific basis for the foundation of OMEICOS. In collaboration with fellow co-founder Dr. John R. Falck, he developed robust synthetic analogues for in vivo administration. The current work of Dr. Schunck is focused on further elucidating the cellular and molecular mechanisms underlying the unique biological properties of 17,18-EEQ and developing new fields of clinical application in collaboration with academic partners and OMEICOS.
Wolf-Hagen Schunck
Wolf-Hagen Schunck is biochemist at the Max Delbrück Center for Molecular Medicine in Berlin-Buch. He has over 30 years of research experience in the field of cytochrome P450 (CYP)-derived bioactive lipid mediators. Dr. Schunck’s laboratory identified 17,18-epoxyeicosatetraenoic acid (17,18-EEQ) laying the scientific basis for the foundation of OMEICOS. In collaboration with fellow co-founder Dr. John R. Falck, he developed robust synthetic analogues for in vivo administration. The current work of Dr. Schunck is focused on further elucidating the cellular and molecular mechanisms underlying the unique biological properties of 17,18-EEQ and developing new fields of clinical application in collaboration with academic partners and OMEICOS.
Rapid Progress Into and Through the Clinic
Since its foundation, OMEICOS has made steady progress towards its goal of developing its core therapeutic approach into and through clinical trials. Thanks to a very lean and efficient drug development organization, the company was able to bring its lead asset OMT-28 into proof-of-concept and dose finding trials in less than 6 years.
2021
2020
October 2020
OMEICOS initiates the planning of 2 new Phase 2 studies with OMT-28 in CV inflammation and mitochondrial diseases
SEPTEMBER 2020
OMEICOS completes Phase 2 clinical study with OMT-28 and progresses 2 more candidates into pre-clinical development
2019
2018
Phase 2
APRIL 2019
OMEICOS initiates Phase 2 clinical trial with OMT-28 focusing on maintenance of sinus rhythm in patients suffering from persistent Atrial Fibrillation
NOVEMBER 2018
OMEICOS announces the closing of a EUR 17 million Series C financing led by new investor Forbion
2017
Phase 1
JULY 2018
OMEICOS Announces compelling first-in-human data on OMT-28 and prepares Phase 2 trial in Atrial Fibrillation
OCTOBER 2017
OMEICOS establishes a US subsidiary to manage future North American operations and secures second tranche of Series B with REMIGES Ventures as new investor
MARCH 2017
OMEICOS initiates Phase 1 clinical trial with OMT-28 and closes first tranche of a Series B with EUR 8.3 million
2015
2014
Pre-Clinical
April 2015
OMEICOS closes Series A round with EUR 6.2 million to take OMT-28 towards clinical trials
JULY 2014
OMEICOS elects OMT-28 as lead compound after completion of a comprehensive pre-clinical assessment
2013
Discovery
JUNE 2013
OMEICOS was spun-out of the Max Delbrück Center for Molecular Medicine to explore the therapeutic potential of stabilized version of epoxyeicosanoids
Learn more about our Pipeline
Our lead candidate OMT-28 has advanced into Phase 2 clinical trials with earlier programs in development
PIPELINE
